GZ BYS PHARMACE -H-
GZ BYS PHARMACE -H- operates in Diversified Metals & Mining.
GZ BYS PHARMACE -H- (GU5) - Net Assets
Latest net assets as of September 2024: €38.05 Billion EUR
Based on the latest financial reports, GZ BYS PHARMACE -H- (GU5) has net assets worth €38.05 Billion EUR as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€79.26 Billion) and total liabilities (€41.20 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €38.05 Billion |
| % of Total Assets | 48.01% |
| Annual Growth Rate | 11.01% |
| 5-Year Change | 41.13% |
| 10-Year Change | N/A |
| Growth Volatility | 4.0 |
GZ BYS PHARMACE -H- - Net Assets Trend (2016–2023)
This chart illustrates how GZ BYS PHARMACE -H-'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GZ BYS PHARMACE -H- (2016–2023)
The table below shows the annual net assets of GZ BYS PHARMACE -H- from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €36.68 Billion | +9.04% |
| 2022-12-31 | €33.64 Billion | +7.38% |
| 2021-12-31 | €31.33 Billion | +11.07% |
| 2020-12-31 | €28.21 Billion | +8.53% |
| 2019-12-31 | €25.99 Billion | +12.30% |
| 2018-12-31 | €23.14 Billion | +20.15% |
| 2017-12-31 | €19.26 Billion | +9.12% |
| 2016-12-31 | €17.65 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to GZ BYS PHARMACE -H-'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 338.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €20.96 Billion | 60.02% |
| Other Components | €13.96 Billion | 39.98% |
| Total Equity | €34.92 Billion | 100.00% |
GZ BYS PHARMACE -H- Competitors by Market Cap
The table below lists competitors of GZ BYS PHARMACE -H- ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AEW UK REIT Plc
LSE:AEWU
|
$20.37K |
|
KWESST Micro Systems Inc. Warrant
NASDAQ:KWESW
|
$20.42K |
|
Mirae Asset Vision Special Purpose Acquisition 3 Co.
KO:448830
|
$20.42K |
|
Vincenzo Zucchi S.p.A.
LSE:0DFF
|
$20.43K |
|
Holloman Energy Corp
PINK:HENC
|
$20.36K |
|
Roxmore Resources Inc.
TO:RM
|
$20.35K |
|
Hanwha Life Insurance Co. Ltd.
KQ:088350
|
$20.32K |
|
FIRSTGROUP
BE:FGR
|
$20.31K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GZ BYS PHARMACE -H-'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 32,065,124,771 to 34,919,280,947, a change of 2,854,156,176 (8.9%).
- Net income of 4,055,678,691 contributed positively to equity growth.
- Dividend payments of 1,585,200,584 reduced retained earnings.
- Other factors increased equity by 383,678,069.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €4.06 Billion | +11.61% |
| Dividends Paid | €1.59 Billion | -4.54% |
| Other Changes | €383.68 Million | +1.1% |
| Total Change | €- | 8.90% |
Book Value vs Market Value Analysis
This analysis compares GZ BYS PHARMACE -H-'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.09x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €11.61 | €2.00 | x |
| 2018-12-31 | €13.34 | €2.00 | x |
| 2019-12-31 | €14.88 | €2.00 | x |
| 2020-12-31 | €16.08 | €2.00 | x |
| 2021-12-31 | €17.88 | €2.00 | x |
| 2022-12-31 | €19.72 | €2.00 | x |
| 2023-12-31 | €21.48 | €2.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GZ BYS PHARMACE -H- utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.61%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.37%
- • Asset Turnover: 0.96x
- • Equity Multiplier: 2.25x
- Recent ROE (11.61%) is below the historical average (12.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 8.69% | 7.53% | 0.77x | 1.49x | €-226.48 Million |
| 2017 | 10.92% | 9.84% | 0.74x | 1.50x | €174.50 Million |
| 2018 | 15.87% | 8.15% | 0.82x | 2.37x | €1.27 Billion |
| 2019 | 13.19% | 4.91% | 1.14x | 2.35x | €770.40 Million |
| 2020 | 11.15% | 4.73% | 1.03x | 2.29x | €300.76 Million |
| 2021 | 12.80% | 5.39% | 1.04x | 2.28x | €813.66 Million |
| 2022 | 12.37% | 5.60% | 0.95x | 2.33x | €760.01 Million |
| 2023 | 11.61% | 5.37% | 0.96x | 2.25x | €563.75 Million |
Industry Comparison
This section compares GZ BYS PHARMACE -H-'s net assets metrics with peer companies in the Other industry.
Industry Context
- Industry: Other
- Average net assets among peers: $114,212,818,724
- Average return on equity (ROE) among peers: -9.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GZ BYS PHARMACE -H- (GU5) | €38.05 Billion | 8.69% | 1.08x | $20.36K |
| HORIBA (01H) | $204.49 Billion | 10.42% | 0.82x | $989.01K |
| Tokyu Corporation (01T) | $779.37 Billion | 3.34% | 2.35x | $99.73K |
| GUANGZHOU AUTO -H- (02G) | $122.28 Billion | 6.59% | 0.55x | $4.05K |
| MOSAIC (02M) | $10.60 Billion | 4.43% | 0.90x | $280.83K |
| MOSAIC (02M.SG) (02M) | $9.56 Billion | 10.46% | 0.82x | $247.21K |
| CHINA JO-JO DRGSTRS (04CN.SG) (04CN) | $16.67 Million | -126.83% | 4.46x | $1.55 Million |
| KRAKATAU STEEL -B- (07K) | $552.59 Million | 3.52% | 4.72x | $166.99 |
| CN MODERN DAIRY (07M) | $7.12 Billion | -10.42% | 1.50x | $1.68K |
| TOURMALINE OIL (08T) | $7.22 Billion | 4.81% | 0.41x | $381.02K |
| ASIA CASSAVA RESOUR (0ACS) | $913.15 Million | 2.86% | 1.55x | $325.03 |